Edetic Acid

Edetic Acid

SCHEMBL1007448

O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.[KH].[KH].[KH].[KH]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.93
EYA2 O00167 1/20 0.93
APP P05067 1/20 0.93
ACE P12821 1/20 0.93
BLM P54132 2/20 0.88
PMP22 Q01453 2/20 0.88
TSHR P16473 2/20 0.88
KDM4E B2RXH2 2/20 0.88
ALOX15 P16050 2/20 0.88
LMNA P02545 1/20 0.88
CHRM2 P08172 1/20 0.88
ADRA2A P08913 1/20 0.88
DRD1 P21728 1/20 0.88
SLC6A2 P23975 1/20 0.88
SLC6A4 P31645 1/20 0.88
CYP2C19 P33261 1/20 0.88
ADRA1A P35348 1/20 0.88
DRD3 P35462 1/20 0.88
SLC6A3 Q01959 1/20 0.88
HRH3 Q9Y5N1 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Edetic Acid SCHEMBL4287868 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL537771 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL120660 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL59497 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL1512912 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL21483279 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL4956709 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL21483277 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL7209772 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL1535300 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250332118-A1 NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA LIVIONEX INC (US) 2025-10-30 US claimed
EP-4637688-A1 ORAL CARE COMPOSITIONS Colgate-Palmolive Company (US) 2025-10-29 EP claimed
US-20250222110-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF AGE-RELATED CATARACTS LIVIONEX INC (US) 2025-07-10 US claimed
US-12324871-B2 Absorbable iron-based alloy implanted medical device and manufacturing method thereof BIOTYX MEDICAL (SHENZHEN) CO., LTD. (CN) 2025-06-10 US claimed
CN-119453173-A Urine protective agent and application thereof 北京清华长庚医院 2025-02-18 CN claimed
EP-4504163-A1 NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA Livionex, Inc. (US) 2025-02-12 EP claimed
CN-119384274-A Novel oral care formulations for the treatment of xerostomia 利维昂尼克斯公司 2025-01-28 CN claimed
CN-115430526-B Composite inhibitor, flotation reagent and method for reverse flotation dephosphorization of phosphorus-containing lithium ore 广州聚源矿业科技有限公司 2024-11-12 CN claimed
WO-2024173395-A1 ORAL CARE COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2024-08-22 WO claimed
WO-2023196667-A1 NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA LIVIONEX, Inc. (US) 2023-10-12 WO claimed
WO-1999064548-A1 SHOWER RINSING COMPOSITION THE CLOROX COMPANY (US) 1999-12-16 WO claimed
US-5972876-A COMPRISING ANIONIC, NONIONIC SURFACTANTS, AND MIXTURES THEREOF, A QUATERNARY AMMONIUM SURFACTANT, WATER-SOLUBLE OR DISPERSIBLE SOLVENT COMPRISING ALKANOLS, DIOLS, GLYCOL ETHERS; ETHYLENEDIAMINETETRAACETIC ACID, TETRAPOTASSIUM SALT CLOROX COMPANY, THE 1999-10-26 US claimed
US-5948741-A MIXTURE OF SURFACTANTS, SOLVENTS, CHELATING AGENT, PROPELLANT AND WATER THE CLOROX COMPANY (US) 1999-09-07 US claimed
EP-0937125-A1 LOW ODOR, HARD SURFACE CLEANER WITH ENHANCED SOIL REMOVAL The Clorox Company (US) 1999-08-25 EP claimed
WO-1998044080-A1 AEROSOL HARD SURFACE CLEANER WITH ENHANCED SOIL REMOVAL THE CLOROX COMPANY (US) 1998-10-08 WO claimed
WO-1998016606-A1 LOW ODOR, HARD SURFACE CLEANER WITH ENHANCED SOIL REMOVAL THE CLOROX COMPANY (US) 1998-04-23 WO claimed
US-4595527-A Chelating agent, ethoxylated phenol or fatty alcohol or ester nonionic surfactant with HLB of 9-13, water S. C. JOHNSON & SON, INC. (US) 1986-06-17 US claimed
US-4530781-A Metastable prespotting composition S. C. JOHNSON & SON, INC. (US) 1985-07-23 US claimed
EP-0137474-A2 Metastable prespotting composition S.C. JOHNSON & SON, INC. (US) 1985-04-17 EP claimed
EP-0137475-A2 Aqueous laundry prespotting composition S.C. JOHNSON & SON, INC. (US) 1985-04-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332118-A1 NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA STOM, TAS2R40, SLC14A1 TDP1 228/4885EYA2 1778/4885APP 4586/4885
US-20250222110-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF AGE-RELATED CATARACTS MSMO1, SLC16A8, SMS TDP1 3882/4885EYA2 279/4885APP 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.